Knoxville Kidney Center | Knoxville, TN

Research site

(Unclaimed)

Location

320 Park 40 North Boulevard, Suite A, Knoxville, Tennessee, United States of America

Site insights

Top conditions

Top treatments

BI 685509

Selonsertib

Iron

Finerenone

MK-2060

EYE103

Phosphate

Ranibizumab

Lesinurad

SYNB8802

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 28 total trials

A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and...

Enrolling

Chronic Kidney Diseases

Type 2 Diabetes Mellitus

Biological: Renal Autologous Cell Therapy (REACT)

Procedure: Sham Comparator

A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME (BRUNELLO)

EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active...

Enrolling

Diabetic Macular Edema (DME)

Drug: EYE103

Drug: Ranibizumab

A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease (FIND-CKD)

Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial treatment, finere...

Active, not recruiting

Non-diabetic Chronic Kidney Disease

Drug: Finerenone (BAY94-8862)

Drug: Placebo

Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)

The purpose of this study is to evaluate the efficacy and safety of two different doses of MK-2060 (a monoclonal antibody against Factor XI) in end s...

Active, not recruiting

End-Stage Renal Disease

End-Stage Kidney Disease

Drug: MK-2060

Drug: Placebo

Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the t...

Active, not recruiting

Diabetic Kidney Disease

Drug: Placebo

Drug: INV-202